CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B
| | | | |

CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B

On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…